News

ReAlta Life Sciences Announces Proof of Mechanism Data from the Phase 1b Inhaled LPS Trial of RLS-0071, Demonstrating Powerful Inhibition of Lung Neutrophils and Inflammatory Cytokines

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced exciting new proof-of-mechanism data from the company’s Phase 1b Inhaled LPS clinical trial of RLS-0071 presented at the American Thoracic Society International Conference on May 23, 2023. RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for HIE and other rare diseases.

“We are excited to share these new data from our Phase 1b trial, which clearly demonstrates the ability of RLS-0071 to dramatically inhibit neutrophil infiltration and pro-inflammatory cytokines such as IL-1ß and IL-8 in a human model of LPS-initiated acute lung disease,” said Ulrich Thienel, Ph.D., M.D., chief executive officer of ReAlta. “The clear translatability of our mechanisms of action from preclinical models to humans encourages our efforts to explore RLS-0071 as a potential therapy for acute pulmonary diseases and other neutrophil-mediated disease processes.”

Findings from the Phase 1b Inhaled LPS trial demonstrated that treatment with RLS-0071 was safe and well-tolerated. Thirty subjects were randomized into three cohorts (10 subjects per cohort) that first inhaled lipopolysaccharide (LPS) and then received three administrations of RLS-0071 at 10 mg/kg (low dose), a 120 mg/kg loading dose followed by two administrations of 40 mg/kg (high dose) or placebo at 1 hour, 8 hours and 16 hours timepoints after the initial LPS inhalation. Blood and sputum were collected for analysis at 6-hour and 24-hour timepoints. Data presented at the American Thoracic Society (ATS) showed that:

RLS-0071 strongly inhibited neutrophil migration into the lungs by 50%

RLS-0071 showed statistically significant reductions in sputum neutrophils, sputum myeloperoxidase (MPO), sputum neutrophil elastase levels and NETosis markers

RLS-0071 also showed clear, meaningful reductions in IL- 1ß and IL-8 pro-inflammatory cytokines

The poster presentation given at ATS by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover, Germany and lead investigator for the study can be downloaded from the Our Science section of the ReAlta website. Based on the data from the Phase 1b Inhaled LPS trial, ReAlta plans further development in neutrophil-mediated pulmonary disease indications.

Learn more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep